Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hemagglutinin of Group 1 Influenza A Virus (HA)
- Target
- HA
- Molecular classification
- Glycoprotein, Viral protein, Class I fusion protein
01
Overview
Hemagglutinin (HA) is a homotrimeric glycoprotein on the surface of influenza A viruses. It mediates attachment to host cells via sialic acid binding and facilitates membrane fusion for viral entry. Group 1 hemagglutinins include subtypes H1, H2, H5, H6, H8, H9, H11, H12, H13, H16, H17, and H18. HA is a major target for neutralizing antibodies and a key component of universal vaccine design efforts.
- Other names
- Group 1 Influenza A HemagglutininH1H2H5H6H8H9H11H12H13H16H17H18
02
Mechanism of action
Neutralizing antibodies block receptor binding or interfere with membrane fusion. Universal vaccine candidates elicit broadly neutralizing antibodies against conserved regions of the hemagglutinin stalk.
03
Biological functions
Host cell attachmentSialic acid bindingMembrane fusionViral entry
04
Disease associations
InfectionInfluenza
05
Safety considerations
Antigenic driftAntigenic shiftDevelopment of resistance to neutralizing antibodies
06
Interacting drugs
Neutralizing antibodies
1 more in the full profile.
Beyond the preview
Go deeper on Hemagglutinin of Group 1 Influenza A Virus (HA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hemagglutinin of Group 1 Influenza A Virus (HA).